Reyon Pharmaceutical Co Ltd (102460) — Capital Reinvestment Ratio
Reyon Pharmaceutical Co Ltd (102460) has a Capital Reinvestment Ratio of 1.76x as of March 2025, meaning it reinvests 2% of its operating cash flow (₩2.41 Billion) in capital expenditures (₩4.25 Billion). See 102460 net asset quality score to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Reyon Pharmaceutical Co Ltd Capital Reinvestment Ratio (2008–2023)
This chart tracks Reyon Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 11 annual periods. Check Reyon Pharmaceutical Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Reyon Pharmaceutical Co Ltd (2008–2023)
Year-by-year Capital Reinvestment Ratio for Reyon Pharmaceutical Co Ltd from 2008 to 2023. For live market cap and broader valuation context, see market cap of Reyon Pharmaceutical Co Ltd.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 3.34x | ₩8.65 Billion | ₩28.87 Billion | ▼ -53.8% |
| 2022 | 7.23x | ₩8.73 Billion | ₩63.13 Billion | ▼ -27.8% |
| 2021 | 10.01x | ₩11.68 Billion | ₩116.98 Billion | ▼ -12.0% |
| 2020 | 11.37x | ₩4.60 Billion | ₩52.31 Billion | ▲ +232.4% |
| 2018 | 3.42x | ₩11.45 Billion | ₩39.17 Billion | ▲ +1284.1% |
| 2017 | 0.25x | ₩16.76 Billion | ₩4.14 Billion | ▼ -27.1% |
| 2016 | 0.34x | ₩9.47 Billion | ₩3.21 Billion | ▲ +245.5% |
| 2012 | 0.10x | ₩24.65 Billion | ₩2.42 Billion | ▼ -37.8% |
| 2011 | 0.16x | ₩15.34 Billion | ₩2.42 Billion | ▼ -6.2% |
| 2009 | 0.17x | ₩8.68 Billion | ₩1.46 Billion | ▼ -51.1% |
| 2008 | 0.34x | ₩5.99 Billion | ₩2.06 Billion | — |